Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1648 • 2015 ACR/ARHP Annual Meeting
The Balance of Foxp3/Ror-Gammat Expression Is Altered By Tocilizumab and By Abatacept in Patients with Rheumatoid Arthritis
Yoshifumi Tada¹, Syuichi Koarada², Nobuyuki Ono², Akihito Maruyama², Satoko Tashiro², Yukiko Tokuda², Yukihide Ono², Yoshinobu Nakao² and Akihide Ohta³, ¹Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ²Rheumatology, Saga University, Saga, Japan, ³Department of Adult and Gerontological Nursing, Saga University School of Medicine, Saga, Japan
Background/Purpose: It has been shown that the balance between Th17 cells and regulatory T (Treg) cells plays an important role for the development of autoimmune…
Abstract Number: 3191 • 2015 ACR/ARHP Annual Meeting
Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages
Takuya Matsumoto¹, Nobunori Takahashi¹, Toshihisa Kojima¹ and Naoki Ishiguro², ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Siglecs (Sialic acid-binding immunoglobulin-type lectins) are type1 transmembrane proteins and expressed on cell surface of various immunocytes. Siglec9 is a member of CD33 related…
Abstract Number: 1656 • 2015 ACR/ARHP Annual Meeting
Repeated CD4+ T-Cell Depletion in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment
Matthieu Lavielle¹, Denis Mulleman¹, Hsueh Cheng Sung², Clément Bahuaud², Philippe Goupille¹, Hervé Watier³ and Gilles Thibault³, ¹Service de Rhumatologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France, ²Université François-Rabelais de Tours, CNRS 7292, Tours, France, ³Laboratoire d'Immunologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France
Background/Purpose: CD4+ T-cell depletion after a first cycle of rituximab (RTX) in patients with rheumatoid arthritis (RA) was previously reported by our group (Mélet J…
Abstract Number: 3198 • 2015 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Ernest H. Choy¹, Corrado Bernasconi², Maher Aassi², Jose F. Molina³ and Oscar M. Epis⁴, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Centro Integral de Reumatologia Reumalab, Medellin, Colombia, ⁴Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
Background/Purpose: ACT-iON was a global, multicenter, observational, 52-wk, clinical practice study of the effectiveness of tocilizumab (TCZ) vs anti–tumor necrosis factor (aTNF) agents prescribed as…
Abstract Number: 1667 • 2015 ACR/ARHP Annual Meeting
Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis
Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Canestri, Clara Di Mario, Marcin Nowik and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Tocilizumab (TCZ) is an effective treatment for Rheumatoid Arthritis (RA) and it is a modifier of B cell subsets in vivo, inducing changes in…
Abstract Number: 175 • 2015 ACR/ARHP Annual Meeting
Correlating Semiquantitative Ultrasound Scores with Measured Synovial Thickness
Ralf G. Thiele¹, Darren Tabechian¹, Laura C Coates² and Jennifer H. Anolik¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine, University of Rochester, Rochester, NY
Background/Purpose: In studies of rheumatoid arthritis using ultrasonography (US), findings of synovial thickening are often reported in semiquantitative scores. For synovial biopsies of small joints,…
Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting
Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Wan-Uk Kim¹, Eun-Jin Han², Chong-Hyeon Yoon³, Ki-Jo Kim⁴, Seung-Ah Yoo⁵, Bong Ki Hong⁵ and Saseong Lee⁵, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴St. Mary's Hospital, Seoul, South Korea, ⁵Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…
Abstract Number: 450 • 2015 ACR/ARHP Annual Meeting
Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: It is well accepted that patients studied in pharmaceutically sponsored clinical trials do not always represent the types of patients seen in clinical practice. …
Abstract Number: 2012 • 2015 ACR/ARHP Annual Meeting
TNF Confers Pathogenic Memory in Synovial Fibroblasts Via Chromatin Remodeling, NF-Kb-Dependent Transcription and MAPK-Mediated mRNA Stabilization
Konstantinos Loupasakis¹, Christopher Sohn², Lionel B. Ivashkiv³ and George D. Kalliolias², ¹Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: We investigated mechanisms driving pathogenic behavior of synovial fibroblasts (FLS) in rheumatoid arthritis (RA). Methods: FLS from RA patients (1987 classification criteria) were extracted.…
Abstract Number: 2507 • 2014 ACR/ARHP Annual Meeting
Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret^®)?
Barbara Missler-Karger¹, Hans-Eckhard Langer², Mika Leinonen³ and Björn Pilström⁴, ¹Rheumatology consultant, Cologne, Germany, ²RHIO Research Institute, Düsseldorf, Germany, ³4Pharma AB, Stockholm, Sweden, ⁴TA Inflammation, Swedish Orphan Biovitrum AB, Stockholm, Sweden
Background/Purpose 458 patients with rheumatoid arthritis (RA) and inadequate response to traditional DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist…
Abstract Number: 1498 • 2014 ACR/ARHP Annual Meeting
ALX-0061, an Anti-IL-6R Nanobody^®foruse in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab
Maarten Van Roy¹, Ariella Van De Sompel², Kristi De Smet², Jasper Jacobs², Tinneke Denayer² and Hans Ulrichts³, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which can either be soluble (sIL-6R) or membrane-bound…
Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting
Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed^4,5, Chitra Karki⁶, Robert Magner⁵, Joel M. Kremer⁷, Ashwini Shewade² and Jeffrey D. Greenberg^6,8, ¹Columbia University, New York, NY, ²Genentech, Inc, South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Corrona, LLC, Southborough, MA, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY, ⁸NYU School of Medicine, New York, NY
Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
Abstract Number: 2501 • 2014 ACR/ARHP Annual Meeting
Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
Stacey Chang¹, Laura Sawyer¹ and Fred Dejonckheere², ¹Symmetron Limited, London, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: Tocilizumab (TCZ) is a recombinant, humanized, monoclonal antibody directed against the cytokine interleukin-6 receptor, and tofacitinib (Tofa) is an oral, synthetic, disease-modifying antirheumatic drug…
Abstract Number: 1494 • 2014 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State
Mate Ongenaert¹, Sonia Dupont², Béatrice Vayssière², Reginald Brys¹, Luc Van Rompaey¹, Christel Menet¹ and René Galien², ¹Galapagos NV, Mechelen, Belgium, ²Galapagos SASU, Romainville, France
Background/Purpose The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that mediate intracellular signaling of cytokines (e.g. certain interleukins and interferons)…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].